November 5, 2021Blood

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Key points are not available for this paper at this time.

Trudel et al. (2021) studied this question.

View Full Paper

Ask AI

Bookmark